OSAKA-GAS
3.8.2022 04:02:06 CEST | Business Wire | Press release
Daigas Gas and Power Solution Co., Ltd. (“DGPS”), a 100% subsidiary of Osaka Gas Co., Ltd. (TOKYO: 9532), has established an expanded business collaboration for onsite hydrogen generator technology with Hyundai Rotem Company (“HRC”), an affiliate of Hyundai Motor Group, allowing HRC to sell the generators outside South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005489/en/
Daigas Group (formerly Osaka Gas Group) launched the first model of “HYSERVE” (*1) , onsite hydrogen generator, in 2003 by adopting its accumulated knowledge on catalyst. DGPS introduced a new model “HYSERVE-300” with hourly hydrogen production capacity of 300 Nm3 in 2013. DGPS, as manufacturer of HYSERVE-300, has sold the units mainly to hydrogen fueling stations.
Then in 2019, DGPS granted HRC to manufacture and sell “Hy-Green”, hydrogen generator utilizing the technology of HYSERVE-300, enabling HRC to meet the increasing demand for hydrogen fueling stations in South Korea.
After confirming HRC’s successful launch of Hy-Green, DGPS has decided to globally deploy its HYSERVE technology through enabling HRC to sell Hy-Green outside of South Korea. DGPS believes this will contribute the prompt buildup of distributed hydrogen supply infrastructure which is necessary for the decarbonization in transportation sector.
Hy-Green will be sold by HRC for the on-site hydrogen fueling station for various hydrogen mobilities (small vehicles, buses, trucks, construction equipment, train, ships, drones and etc), fuel cell power plant, and biogas production facilities (to produce hydrogen) in order to expand the hydrogen supply chain.
HRC has already developed mass production capacity of Hy-Green and is ready for receiving inquiries from the world including those through Daigas Group.
Daigas Group including DGPS is going to expand its overseas energy business from upstream to downstream by fully utilizing its experiences in and out of Japan and its existing overseas business platforms.
(*1) |
Onsite hydrogen generator developed and sold by Daigas Group. 36 units have been sold in Japan so far. |
|
[Press Release on the launch of HYSERVE-300 (in Japanese)] |
|
https://www.osakagas.co.jp/company/press/pr_2013/1206060_7831.html |
| [Corporate Profile] | |||
| Osaka Gas Co., Ltd. | |||
Head Office: |
4-1-2 Hiranocho, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Masataka Fujiwara (President & Representative Director) |
||
Amount of Capital: |
132,166,660,000 JPY |
||
Date of Establishment: |
April 10, 1897 |
||
Business Outline: |
Natural gas distribution and supply; power generation and supply, etc. |
||
| Daigas Gas and Power Solution Co., Ltd. | |||
Head Office: |
3-5- 11 Doshomachi, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Nobushige Goto (President & Representative Director) |
||
Amount of Capital: |
100,000,000 JPY |
||
Date of Establishment: |
October 1, 2019 |
||
Business Outline: |
Operation and maintenance of gas and power plants; power generation and supply; and engineering |
||
| Hyundai Rotem Company | |||
Head Office: |
37, Cheoldobangmulgwan-ro, Uiwang-si, Gyeonggi-do, 16082, Korea |
||
Representative: |
Yong-Bae, Lee (CEO) |
||
Amount of Capital: |
545,711,465,000 KRW |
||
Date of Establishment: |
July 1, 1977 |
||
Business Outline: |
Total railway systems supply, Ground weapon systems supply, Steel, automobile production and hydrogen infrastructures supply, etc. |
||
Contact Detail: |
Duseop Lee / duseop.lee@hyundai-rotem.co.kr / +82-10-2648-5039 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
